Acute Myeloid Leukemia
Specialty Channel

Featured Article
WGS could be an alternative to conventional cytogenetic analysis in patients with AML or MDS, according to Eric J. Duncavage, MD, et al.
Phase 2 study findings demonstrate the clinical efficacy of pevonedistat plus azacitidine for the treatment of higher-risk MDS and low-blast AML.
The FDA has cleared an Investigational New Drug application for VOR33, an engineered hematopoietic stem cell therapy for the treatment of certain patients with AML.
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.
What is the mechanism of action of sabatolimab therapy in patients with intermediate- to high-risk MDS and/or AML?
In a phase 3 study of older patients with AML in remission after chemo, maintenance therapy with CC-486 was tied to significantly longer survival than placebo.
Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.

News

WGS could be an alternative to conventional cytogenetic analysis in patients with AML or MDS, according to Eric J. Duncavage, MD, et al.
Phase 2 study findings demonstrate the clinical efficacy of pevonedistat plus azacitidine for the treatment of higher-risk MDS and low-blast AML.
The FDA has cleared an Investigational New Drug application for VOR33, an engineered hematopoietic stem cell therapy for the treatment of certain patients with AML.
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.

Interactive Features

What is the mechanism of action of sabatolimab therapy in patients with intermediate- to high-risk MDS and/or AML?
Findings from which clinical trial led to the FDA approval of azacitidine as maintenance therapy for patients with AML?
Which of the following approaches has shown promise in personalizing therapy for patients with relapsed or refractory AML?
True or False: A recent study demonstrated favorable responses when combining azacitidine with enasidenib, for patients with newly diagnosed IDH2-mutated AML.
Stay in the know.
OncNet Newsletter